期刊文献+

低分子肝素钠治疗肺心病并心力衰竭效果观察 被引量:4

Effect of low molecular heparin sodium in the treatment of pulmonary heart disease combined with heart failure
下载PDF
导出
摘要 目的观察低分子肝素钠治疗肺心病并心力衰竭的临床效果。方法选取我院2013年7月~2015年9月收治的肺心病并心力衰竭患者89例,按入院时间先后分为对照组(44例)、观察组(45例),给予对照组综合治疗,给予观察组以对照组为基础加用低分子肝素钠治疗,对比两组治疗前后的实验室指标、临床效果及不良反应发生率。结果治疗后两组血浆粘度、全血粘度、红细胞数、红细胞压积、纤维蛋白原定量及凝血酶原时间较治疗前明显改善,其中观察组改善程度优于对照组(P〈0.05)。观察组总有效率93.33%(42/45)明显高于对照组的79.55%(35/44),差异有统计学意义(P〈0.05)。观察组并发症发生率6.67%(3/45)显著低于对照组的27.27%(12/44),差异有统计学意义(P〈0.05)。结论低分子肝素钠治疗肺心病并心力衰竭,疗效确切,改善心功能与各项指标,安全性高,值得推广。 Objective To explore the clinical effect of low molecular heparin sodium in the treatment of pulmonary heart disease combined with heart failure. Methods 89 patients with pulmonary heart disease and heart failure who were in our hospital from July 2013 to September 2015 were divided into control group(44 cases) and observation group(45 cases) according to their admission time. The control group received complex treatment, and the observation group was treated with low molecular heparin sodium based on complex treatment. The laboratory indices, clinical effects, and adverse reaction incidences before and after treatment of the two groups were compared. Results After treatment, the plasma viscosities, whole blood viscosities, red blood counts, hematokrits,fibrinogen quantities and prothrombin time in the two groups were better than those before intervention, and the improvements in the observation group were superior than those of the control group(P〈0.05).The total effective rate of the observation group was 93.33%(42/45),which was obviously higher than the 79.55%(35/44) of the control group, the difference was statistically significant(P〈0.05).The complication rate of the observation group was 6.67%(3/45),which was obviously lower than the 27.27%(12/44)of the control group, the difference was statistically significant(P〈0.05). Conclusion The low molecular heparin sodium has a clear effect in the treatment of pulmonary heart disease combined with heart failure, which can improve the patients' heart functions with high safety.It is worthy of being promoted.
出处 《中国医药科学》 2016年第8期196-198,共3页 China Medicine And Pharmacy
关键词 肺心病 心力衰竭 低分子肝素钠 临床效果 Pulmonary heart disease Heart failure Low molecular heparin sodium Clinical effect
  • 相关文献

参考文献15

二级参考文献59

  • 1柳元化,邵学平.脂微球前列腺素E_1治疗急性呼吸窘迫综合征疗效评估[J].临床医学,2004,24(7):12-14. 被引量:1
  • 2邓祎,陈粉合.低分子肝素脂微球前列腺素E1治疗肺心病心衰临床观察[J].中国急救医学,2004,24(12):932-932. 被引量:6
  • 3翁心植.肺心病伴发冠心病的诊断与鉴别诊断[J].中华内科杂志,1982,21:239-242.
  • 4唐学义 郑素歌 等.慢性肺心病患者血小板活化程度及其与缺氧关系的研究[J].中国实用内科杂志,2000,20(7):400-400.
  • 5陶仲为.慢性肺心病并高粘血症[J].山东医药,1985,4(1):22-22.
  • 6[4]Hirsh J,Levine MN.Low molecular weight heparin[J].Blood,1992,79(1):1-17.
  • 7苗淑贤,陈素礼.低分子肝素治疗肺心病临床研究[J].中国实用内科杂志,2001,24(12):728.
  • 8陈新谦 金有豫.新编药物学(第14版)[M].北京:人民卫生出版社,2001.154-159.
  • 9赵水平.肺原性心脏病[M].长沙:湖南科学技术出版社,2000:146.
  • 10叶任高.内科学[M]北京:人民卫生出版社,200487.

共引文献134

同被引文献32

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部